May 2008
BioWorld Today;5/8/2008, Vol. 19 Issue 90, p2
This section offers news briefs concerning the U.S. biopharmaceutical industry. Emergent BioSolutions, Inc. has posted increased revenues and a net income of $7 million or 24 cents per share for the first quarter of 2008. The total sales generated by Onyx Pharmaceuticals, Inc. for its Nexavar totaled $151.9 million for the first quarter of 2008.


Related Articles

  • TOP STORIES.  // MondayMorning;9/2/2013, Vol. 21 Issue 31, p1 

    The article offers news briefs related to the pharmaceutical industry in the U.S. as of September 2, 2013. Amgen Inc. will acquire fellow biotechnology firm Onyx Pharmaceuticals Inc. for $10.4 billion. The revenue of MGC Diagnostics Corp. has increased by 15% year over year to $7.9 million in...

  • Pharmaceutical sector sees flurry of acquisitions.  // Chain Drug Review;9/9/2013, Vol. 35 Issue 14, p13 

    The article offers information on several acquisitions in the U.S. pharmaceutical industry including the purchase of Onyx Pharmaceuticals Inc. by Amgen Inc., acquisition of Hi-Tech Pharmacal Co. by Akorn Inc. and purchase of Amplimmune Inc. by AstraZeneca PLC.

  • EMERGENT BIOSOLUTIONS PROVIDES 2010 FINANCIAL GUIDANCE.  // Biotech Financial Reports;Feb2010, Vol. 17 Issue 2, p4 

    The article presents Emergent BioSolutions Inc.'s financial outlook for 2010 in Rockville, Maryland. The company forecasts that its total revenue will reach approximately 235-255 million U.S. dollars due to the deliveries of BioThrax vaccines. It predicts that its net income will hit 20-30...

  • Emergent BioSolutions Reports Financial Results for 3rd Qtr and First 9 Months of 2011.  // Biomedical Market Newsletter;11/9/2011, Vol. 21, p382 

    The article reports that Emergent BioSolutions Inc. will host a conference call on November 3, 2011 to discuss its third quarter 2011 financial results. Accordingly, chief financial officer (CFO) R. Don Elsey will present a decreased corporate performance as of September 30, 2011. Emergent will...

  • Emergent BioSolutions Reports Financial Results for 2nd Quarter and First Six Months of 2012.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article focuses on the financial performance of Emergent BioSolutions Inc. in the second quarter and first six months of 2012. It informs that the total revenue of the company in 2012 was 70.4 million U.S. dollars and 120.7 million U.S. dollars in the first six months of 2012. It reports...

  • Precious Mettle. Comer, Benjamin // Pharmaceutical Executive;Jul2011, Vol. 31 Issue 7, p28 

    The article highlights the role of Tony Coles as chief executive officer (CEO) at Onyx Pharmaceuticals Inc. in leading the company to greater heights in the U.S. It recounts how the condition of his son having a compromising mediastinal mass has influenced his craft in discovering new compounds,...

  • COMPANY SPOTLIGHT - Onyx Pharmaceuticals, Inc.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p24 

    The article presents a company profile for Onyx Pharmaceuticals Inc., a U.S.-based biopharmaceutical company engaged in research and development of drugs for cancer treatment. Nexavar or sorafenib, a kinase and angiogenesis inhibitor for targeting signal pathways for the proliferation of cancer...

  • Onyx Boosted By Increase In Sales Of Cancer Drug Nexavar.  // BioWorld Today;8/9/2007, Vol. 18 Issue 154, p2 

    The article reports on the increased second quarter sales obtained by Onyx Pharmaceuticals Inc. on its cancer drug Nexavar. The company shares that Nexavar revenues rose by 34 percent from the first quarter ended June 30, 2007 and 150 percent from a year ago. Onyx president and chief executive...

  • Emergent BioSolutions Provides Preliminary 2011 Financial Results and Provides Guidance for 2012.  // Biomedical Market Newsletter;1/14/2012, Vol. 21, p1 

    The article provides information on the announcement by vaccines and therapeutics manufacturing company, Emergent BioSolutions Inc. The company announced the preliminary 2011 financial results and provided guidance for 2012. The company provides total revenues, net income, intangible assets,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics